PA-VIACLEAN-TECHNOLOGIES
14.7.2021 08:17:09 CEST | Business Wire | Press release
ViaClean Technologies, LLC , a Philadelphia-based biotech company, jointly with its distributor and business development partner, Bizos Cavallo Enterprises LLC of Dallas, TX, and their partner, V-Clean Technologies S.A. of Athens, Greece, jointly announced the country of Greece's approval for the use of BIOPROTECT™ RTU on porous and non-porous surfaces in the fight against SARS-CoV-2. Greece has recognized BIOPROTECTTM RTU as inhibiting the growth of harmful bacteria and viruses, including SARS-CoV-2 (COVID virus), on surfaces for up to 90 days.
Having accepted and recognized the antimicrobial surface efficacy of BIOPROTECT™ RTU, Greece's National Organization of Medicines (ΕΟΦ) has approved the unrestricted consumer use of BIOPROTECT™ RTU to inhibit the growth of SARS-CoV-2 and other harmful viruses, bacteria, mold, and mildew, on treated surfaces. This innovative technology has proven to be effective for up to 90 days and has been applied in various public and private environments in Greece, including medical facilities, mass transit, education, commercial facilities, and more.
"ViaClean has been committed to supporting the reopening of Europe throughout the past year, hoping to instill a sense of normality as people navigate these unprecedented times," said ViaClean President and CEO, Greg Tipsord. "With Greece's adoption of BIOPROTECTTM RTU antimicrobial surface protectant, which inhibits the growth of SARS-CoV-2 and other harmful viruses and bacteria on surfaces, we believe Greece will benefit from this proven technology and strengthen their commitment to reach pre-pandemic levels of normalcy for their citizens. We've delivered an effective antimicrobial surface protectant solution that supports our mission of continued research, innovation, and dedication on a global scale."
"At V-Clean Technologies S.A., we have further cemented our commitment to Greece and the ongoing safety of our fellow citizens and visitors through our commitment to bringing innovative, patented technologies to our country to reduce the presence of bacteria, germs, fungi, algae, and other problematic micro-organisms including SARS CoV-2” said Panos Sofianos, President of V-Clean. “We thank the Greek government, and specifically the Ministry of Health and the National Organisation for Medicines (ΕΟΦ), our joint-venture distribution partner, Bizos Cavallo Enterprises and of course, ViaClean Technologies, for their rigor, diligence, and support throughout this process."
In Greece and in other European Member States, where regulatory approvals are pending, the unique non-leaching and non-volatile BIOPROTECTTM RTU formula has proven to be effective at killing harmful microbes and reducing odors for up to 90 days on various surfaces. "We are fortunate and thrilled to have partnered with both V-Clean Technologies and ViaClean Technologies by facilitating the approval process and distribution of BIOPROTECTTM RTU antimicrobial surface protectant for Greece," said Elvin Thibodeaux, Managing Partner of Bizos Cavallo Enterprises. "Our continued efforts will supply this innovative technology exclusively to additional markets, including the European Union and Balkan Peninsula, Russia and more, that are pursuing dynamic relief from the effects of the pandemic over the past 18 months."
In the United States, ViaClean markets the BIOPROTECTUs™ System, which uses patented, registered technologies: SmartTouch®, a List N disinfectant, to disinfect surfaces against viruses, bacteria, and germs, and BIOPROTECT™ RTU antimicrobial surface protectant, to keep surfaces free of odor- and stain-causing bacteria, fungi (mold and mildew), and algae between cleanings, for up to 90 days (3 months). In the United States, however, BIOPROTECT™ RTU is not currently approved or available for use against the SARS-CoV‑2 virus, other viruses, harmful bacteria, or any other harmful microorganisms.
Additional products offered from ViaClean and Bizos Cavallo in the United States, and pending approval in Greece, include the registered BIOPROTECT™ 500 concentrate, registered BIOPROTECTTM D disinfectant, and registered BIOPROTECT™ Hydrating Hand Sanitizer. For more information on ViaClean Technologies and The BIOPROTECTUs™ System, please visit bioprotectworldwide.com . For information on the aforementioned markets or sales with Bizos Cavallo Enterprises, visit www.bizoscavallo.com.
About ViaClean Technologies. LLC
ViaClean Technologies LLC is a biotech company that develops, manufactures, and markets groundbreaking, innovative antimicrobial solutions using environmentally responsible manufacturing processes. ViaClean Technologies' pioneering and proprietary technologies, products, and services provide disinfectants, antimicrobial protectants, and hand sanitizers for commercial and consumer use. ViaClean Technologies' primary mission is to market these advanced antimicrobial formulations to critical industries, manufacturing the registered formulations using environmentally responsible processes. For more information, visit the ViaClean website (bioprotectworldwide.com ).
About V-Clean Technologies, S.A.
V-Clean Technologies S.A. is a biotechnology firm based in Athens, Greece that is focused on developing and marketing cutting edge technologies, products and services to meet the challenges and opportunities in Europe, Russia and the Middle East. In conjunction with our pharmaceutical affiliates and partners we strive for innovative and environmentally responsible solutions in an ever-changing marketplace. Having created a strong and sustainable network of strategic partners throughout these regions, we are able to be proactive and effective in providing services ranging from manufacturing, sourcing, logistics and regulatory advisory. For more information about V-Clean Technologies S.A. please visit our website (www.virusclean.gr ).
About Bizos Cavallo Enterprises, LLC
Bizos Cavallo Enterprises, LLC is a strategic consulting and operations firm focused on emerging bioscience innovations for public health, strategic alliances, and global investment resources based in Dallas, TX, with offices in New Orleans, LA, and Winston-Salem, NC. In addition, Bizos Cavallo owns the subsidiary, BP&D International, LLC, a global leader in the procurement and the export of premium cultural commodities, including bulk grains, animal proteins, and their respective derivatives. Founded in 2017, Bizos Cavallo's network includes partners and a host of strategic alliances in the United States, Greece, China, South Korea, Japan, Singapore, Dubai, France, Brazil, the West Indies and trade operations in the United Kingdom. For more about Bizos Cavallo, visit the Bizos Cavallo Enterprises website (www.bizoscavallo.com ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713006244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom